Synopsis Intracerebral hemorrhage (ICH) is one of the major neurological diseases affecting more than two million people each year. In patients with ICH, iron is released after hemoglobin degradation and hemolysis of red blood cells. The iron can trigger other associated complications such as apoptosis, oxidative stress, inflammation, and autophagy. The presence of iron chelating agents at this point of ICH can exert neuroprotective action.
In the present clinical trial, one such iron-chelating agent deferoxamine (DFO) is tested for its safety in treating patients with the onset of ICH. This Journal Watch discusses the study “ Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial,” from The Lancet Neurology Journal. Authors : Madgy Selim, Lydia D Foster, Claudia S Moy, et al What was the need…
